Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million.

Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a 13% discount to its Monday close of $28.01, when the company proposed the offering after market close. Horizon was up $0.34 to $25.82 on Thursday...